内科理论与实践 ›› 2024, Vol. 19 ›› Issue (01): 25-31.doi: 10.16138/j.1673-6087.2024.01.05
揭志军, 沙家凤, 张萌
收稿日期:
2023-09-19
出版日期:
2024-02-29
发布日期:
2024-04-28
基金资助:
JIE Zhijun, SHA Jiafeng, ZHANG Meng
Received:
2023-09-19
Online:
2024-02-29
Published:
2024-04-28
摘要:
新型冠状病毒(新冠)感染全球形势依然严峻。随着疫情持续发展,重复感染风险显著增加。新冠疫苗接种史、既往感染史、抗体水平、年龄及免疫逃逸等都可以影响重复感染的发生。科学的康复训练能够缓解新冠感染后遗症。疫苗接种仍然是一种重要的预防手段。本文对新冠的流行形势和重复感染现状、重复感染的影响因素以及应对等方面进行讨论,为疫情防控提供借鉴和参考。
中图分类号:
揭志军, 沙家凤, 张萌. 新型冠状病毒重复感染和应对[J]. 内科理论与实践, 2024, 19(01): 25-31.
JIE Zhijun, SHA Jiafeng, ZHANG Meng. Reinfection of COVID-19 and response[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(01): 25-31.
[1] | WHO. WHO coronavirus (COVID-19) dashboard[EB/OL]. 2023. https://covid19.who.int/. |
[2] | WHO. COVID-19 epidemiological update - 24 November 2023[EB/OL]. 2023. https://www.who.int/publications/m/item/covid-19-epidemiological-update---24-november-2023 |
[3] |
Klaassen F, Chitwood MH, Cohen T, et al. Changes in population immunity against infection and severe disease from severe acute respiratory syndrome coronavirus 2 omicron variants in the United States between December 2021 and November 2022[J]. Clin Infect Dis, 2023, 77(3): 355-361.
doi: 10.1093/cid/ciad210 URL |
[4] | Bastard J, Taisne B, Figoni J, et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022[J]. Euro Surveill, 2022, 27(13):2200247. |
[5] |
Guedes AR, Oliveira MS, Tavares BM, et al. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic[J]. Sci Rep, 2023, 13(1): 712.
doi: 10.1038/s41598-022-25908-6 pmid: 36639411 |
[6] | Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. Rate of SARS-CoV-2 reinfection during an Omicron wave in iceland[J]. JAMA Netw Open, 2022, 5(8):e2225320. |
[7] | 戴映雪, 王瑶, 杜训波, 等. 成都市新冠病毒既往感染者重复感染Omicron变异株情况分析[J]. 中国公共卫生, 2023, 39(4): 442-447. |
[8] |
Lin M, Cao K, Xu F, et al. A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China[J]. Emerg Microbes Infect, 2023, 12(2):2261559.
doi: 10.1080/22221751.2023.2261559 URL |
[9] | Yu W, Guo Y, Hu T, et al. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China[J]. J Med Virol, 2023, 95(8):e28997. |
[10] |
Wang Y, Liang J, Yang H, et al. Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province[J]. Front Public Health, 2023, 11:1256768.
doi: 10.3389/fpubh.2023.1256768 URL |
[11] | Kissler SM, Hay JA, Fauver JR, et al. Viral kinetics of sequential SARS-CoV-2 infections[EB/J]. medRxiv, 2023. https://www.medrxiv.org/content/10.1101/2023.03.03.23286775v1. |
[12] | Hadley E, Yoo YJ, Patel S, et al. SARS-CoV-2 reinfection is preceded by unique biomarkers and related to initial infection timing and severity[EB/J]. medRxiv [Preprint], 2023.https://doi.org/10.1101/2023.01.03.22284042. |
[13] |
Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 reinfections as compared with primary infections[J]. N Engl J Med, 2021, 385(26):2487-2489.
doi: 10.1056/NEJMc2108120 URL |
[14] |
Mensah AA, Lacy J, Stowe J, et al. Disease severity during SARS-COV-2 reinfection[J]. J Infect, 2022, 84(4):542-550.
doi: 10.1016/j.jinf.2022.01.012 URL |
[15] |
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection[J]. Nat Med, 2022, 28(11):2398-2405.
doi: 10.1038/s41591-022-02051-3 pmid: 36357676 |
[16] |
Cavanaugh AM, Spicer KB, Thoroughman D, et al. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination - Kentucky, May-June 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(32):1081-1083.
doi: 10.15585/mmwr.mm7032e1 URL |
[17] |
Gazit S, Shlezinger R, Perez G, et al. The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine[J]. Ann Intern Med, 2022, 175(5):674-681.
doi: 10.7326/M21-4130 URL |
[18] |
Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from COVID-19[J]. N Engl J Med, 2022, 386(13):1221-1229.
doi: 10.1056/NEJMoa2119497 URL |
[19] | Ye C, Zhang G, Zhang A, et al. The Omicron variant reinfection risk among individuals with a previous SARS-CoV-2 infection within one year in Shanghai, China[J]. Vaccines (Basel), 2023, 11(7):1146. |
[20] |
Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil[J]. Lancet Infect Dis, 2022, 22(6):791-801.
doi: 10.1016/S1473-3099(22)00140-2 pmid: 35366959 |
[21] |
COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection[J]. Lancet, 2023, 401(10379): 833-842.
doi: 10.1016/S0140-6736(22)02465-5 URL |
[22] |
Powell AA, Kirsebom F, Stowe J, et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022[J]. Lancet Infect Dis, 2023, 23(4):435-444.
doi: 10.1016/S1473-3099(22)00729-0 URL |
[23] |
Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore[J]. Lancet Infect Dis, 2023, 23(7): 799-805.
doi: 10.1016/S1473-3099(23)00060-9 URL |
[24] |
Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers[J]. New Engl J Med, 2021, 384(6): 533-540.
doi: 10.1056/NEJMoa2034545 URL |
[25] | Finch E, Lowe R, Fischinger S, et al. SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort[J]. PLoS Biol, 2022, 20(2):e3001531. |
[26] | Michlmayr D, Hansen CH, Gubbels SM, et al. Observed protection against SARS-CoV-2 reinfection following a primary infection[J]. Lancet Reg Health Eur, 2022, 20:100452. |
[27] |
Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2[J]. Nature, 2021, 596(7872):417-422.
doi: 10.1038/s41586-021-03739-1 |
[28] | Mazagatos C, Monge S, Olmedo C, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021[J]. Euro Surveill, 2021, 26(24):2100452. |
[29] |
Palacios-Pedrero MÁ, Jansen JM, Blume C, et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults[J]. Nat Aging, 2022, 2(10): 896-905.
doi: 10.1038/s43587-022-00292-y pmid: 37118289 |
[30] |
Li M, Peng H, Duan G, et al. Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant[J]. Front Public Health, 2022, 10:1014470.
doi: 10.3389/fpubh.2022.1014470 URL |
[31] |
Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020[J]. Lancet, 2021, 397(10280):1204-1212.
doi: 10.1016/S0140-6736(21)00575-4 URL |
[32] | 张戈, 张安冉, 贾逸林, 等. 上海市浦东新区新冠病毒重复感染情况分析[EB/J]. 上海预防医学, 2023. https://kns.cnki.net/kcms2/article/abstract?v=smPsKIJgVaAYWg3fyvJbRxd88NUnMspFJv9V6LXB6zr56O7fU8X9zY_z9gu0Ik51p3j_gyp3zac8piy_F_GNfPIjzWO2LFZzmAOYZGc1hudgNqVcywJPPuGjKAxFH_7YyCFtLrc86OE=&uniplatform=NZKPT&language=CHS. |
[33] | Washington State Department of Health. Reported COVID-19 reinfections in Washington State[EB/OL]. 2022. https://doh.wa.gov/sites/default/files/2022-02/421-024-ReportedReinfections.pdf. |
[34] | Ferguson N, Ghani A, Cori A, et al. Growth, population distribution and immune escape of Omicron in England[EB/OL]. 2021. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-16-COVID19-Report-49.pdf. |
[35] | Chen X, Xu Y, Xie Y, et al. Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection[J]. Lancet Reg Health West Pac, 2023, 33:100758. |
[36] | 陆婉莹, 陈鑫华, 郑楠, 等. 新型冠状病毒原型株有症状感染者中和抗体水平对奥密克戎亚型BA.1、BA.4和BA.5的保护概率预测[J]. 中华医学杂志, 2023, 103(18): 1429-1434. |
[37] |
Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants[J]. N Engl J Med, 2022, 387(17):1620-1622.
doi: 10.1056/NEJMc2209306 URL |
[38] |
Chemaitelly H, Tang P, Coyle P, et al. Protection against reinfection with the Omicron BA.2.75 subvariant[J]. N Engl J Med, 2023, 388(7):665-667.
doi: 10.1056/NEJMc2214114 URL |
[39] | Chen JJ, Li LB, Peng HH, et al. Neutralization against XBB.1 and XBB.1.5 after Omicron subvariants breakthrough infection or reinfection[J]. Lancet Reg Health West Pac, 2023, 33:100759. |
[40] | Paliani U, Cardona A, Gili A, et al. Impact of rehabilitation treatment during the acute phase of SARS-CoV-2 infection[EB/J]. Eur J Intern Med, 2023. https://www.ejinme.com/article/S0953-6205(23)00415-6/abstract. |
[41] | de Araújo Furtado PL, do Socorro Brasileiro-Santos M, de Mello BLC, et al. The effect of telerehabilitation on physical fitness and depression/anxiety in post-COVID-19 patients[J]. Int J Telerehabil, 2023, 15(1):e6560. |
[42] | WHO. Support for rehabilitation: self-management after COVID-19-related illness, second edition 2021[EB/OL]. 2021. https://iris.who.int/handle/10665/344472. |
[43] | 国务院联防联控机制综合组. 《近期重点人群新冠病毒疫苗接种工作方案》解读[EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202307/d5968788cfee4caf8087955d470fd306.shtml. |
[44] |
Tan ST, Kwan AT, Rodríguez-Barraquer I, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave[J]. Nat Med, 2023, 29(2):358-365.
doi: 10.1038/s41591-022-02138-x pmid: 36593393 |
[45] |
Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection[J]. Nat Rev Immunol, 2021, 21(6): 395-404.
doi: 10.1038/s41577-021-00550-x pmid: 33927374 |
[1] | 赖柏翰, 魏伯轩, 金佳敏, 等. 中国先天性巨大黑痣的流行病学以及危险因素调查研究[J]. 组织工程与重建外科杂志, 2025, 21(3): 250-. |
[2] | 张计委, 吴小琼, 崔金煌, 俞春明, 黎衍云. 中老年人群糖代谢状态与全因死亡及心脑血管疾病死亡风险的关联研究[J]. 内科理论与实践, 2025, 20(02): 120-125. |
[3] | 沈世仲, 隋亮, 陈康, 史晓, 施丹. “肾藏精,主骨”理论与男性骨质疏松症[J]. 内科理论与实践, 2025, 20(01): 94-100. |
[4] | 刘嘉琳, 张莉. 中西医结合呼吸康复治疗在新型冠状病毒肺炎中的研究进展[J]. 内科理论与实践, 2025, 20(01): 63-66. |
[5] | 秦野1,陈蓉蓉2. 基于社会网络分析方法的新型冠状病毒肺炎相关国际科研合作研究[J]. J Shanghai Jiaotong Univ Sci, 2024, 29(1): 150-160. |
[6] | 洪冬羊1,3, 王金霞2,3, 张虹洋2,3, 曹紫阳2,3, 晏紫君2,3, 邹琳2,3. 2022年新型冠状病毒肺炎疫情对中国大学生心理影响[J]. J Shanghai Jiaotong Univ Sci, 2024, 29(1): 141-149. |
[7] | 陈微微, 孙良丹. 中国人群银屑病遗传流行病学研究进展[J]. 诊断学理论与实践, 2024, 23(06): 561-567. |
[8] | 苏琪莹, 王虹晓, 阎骅. 实体瘤细胞毒治疗后罹患髓系肿瘤的研究进展[J]. 内科理论与实践, 2024, 19(06): 427-430. |
[9] | 范凯健, 刘金渝, 赵福涛. 重视干燥综合征的早期诊断[J]. 内科理论与实践, 2024, 19(06): 417-421. |
[10] | 谢晓萌, 龚艳春. 老年餐后低血压及其心脑血管损害的研究进展[J]. 内科理论与实践, 2024, 19(05): 342-346. |
[11] | 李雅洁, 崔岱. 亚急性甲状腺炎诊治新进展[J]. 内科理论与实践, 2024, 19(04): 259-263. |
[12] | 李晨曦, 胡蕴, 吴文君. 胰腺脂肪沉积与动脉粥样硬化的关联研究进展[J]. 内科理论与实践, 2024, 19(04): 278-282. |
[13] | 孙以亚, 罗庆志, 金奇, 吴立群. 导管消融治疗心房颤动合并射血分数保留型心力衰竭患者的临床进展[J]. 内科理论与实践, 2024, 19(03): 188-192. |
[14] | 王刚, 齐金蕾, 刘馨雅, 任汝静, 林绍慧, 胡以松, 李海霞, 谢心怡, 王金涛, 李建平, 朱怡康, 高梦伊, 杨竣杰, 王怡然, 井玉荣, 耿介立, 支楠, 曹雯炜, 徐群, 余小萍, 朱圆, 周滢, 王琳, 高超, 李彬寅, 陈生弟, 袁芳, 窦荣花, 刘晓云, 李雪娜, 尹雅芙, 常燕, 徐刚, 辛佳蔚, 钟燕婷, 李春波, 王颖, 周脉耕, 陈晓春, 代表中国阿尔茨海默病报告编写组. 中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(03): 219-256. |
[15] | 黄睿, 饶慧瑛. “消除”背景下的丙型肝炎病毒感染现状及筛查、诊断对策[J]. 诊断学理论与实践, 2024, 23(01): 1-8. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||